Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 267

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1B
Chunk 267
---

    )

    Net cash (used in) provided by investing activities

    (230,994
    )

    128,378

    Cash provided by financing activities

    203,291

    163,997

    Net (decrease) increase in cash and cash equivalents
     
    $
    (105,816
    )
     
    $
    145,522

Operating activities 

Net cash used in operating activities for the year ended December 31, 2024 was $78.1 million consisting of our net loss of $95.5 million and non-cash charges of $9.1 million, which were offset by changes in net operating assets and liabilities of $26.5 million. Non-cash charges consisted primarily of a gain from sale of PRV of $108.0 million and accretion of discounts on short-term investments of $6.4 million partially offset by acquired in-process research and development assets of $55.0 million, shared-based compensation expense of $48.3 million, amortization of intangible assets of $1.5 million, and amortization of operating right-of-use asset of $0.5 million. Changes in operating assets and liabilities were primarily related to increases in accrued expenses and other current liabilities of $42.1 million, deferred revenue of $4.8 million, accounts payable of $0.7 million, other long-term liability of $0.8 million, and a decrease in deposits and other long-term assets of $0.1 million. This was partially offset by an increase in accounts receivable of $13.9 million, prepaid expenses and other current assets of $4.6 million, inventory of $3.2 million, and a decrease of operating lease liabilities of $0.3 million.

Net cash used in operating activities for the year ended December 31, 2023 was $146.9 million, consisting of our net loss of $188.9 million, changes of approximately $9.5 million in net operating assets and liabilities and by non-cash charges of $32.6 million, which is primarily comprised of share-based compensation expense of $39.3 million. Changes in operating assets and liabilities were primarily related to an increase in accrued expenses and other current liabilities of $10.6 million and accounts payable of $2.3 million and a decrease in deposits and other long-term assets of $0.3 million. This was partially offset by an increase of prepaid expenses and other current assets of